NIKKEI 225
39,667.07 +493.92 (+1.26%) HANG SENG
18,089.93 +17.03 (+0.09%) CRUDE OIL
80.92 +0.09 (+0.11%) GOLD FUTURES
2,310.60 -20.20 (-0.87%) DOW
39,155.09 +42.93 (+0.11%) Bitcoin GBP
48,480.51 -147.05 (-0.30%)
REGN Nov 2024 950.000 call
| Previous close | 135.50 |
| Open | 69.60 |
| Bid | 155.90 |
| Ask | 164.60 |
| Strike | 950.00 |
| Expiry date | 2024-11-15 |
| Day's range | 135.50 - 138.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Simply Wall St.Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 45% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,936 based on 2 Stage Free Cash Flow to...
ZacksRegeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
GlobeNewswireUpdated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
